Parexel: M&A likely to continue despite $200m stock repurchase plan

By Dan Stanton contact

- Last updated on GMT

CRO Parexel is listed on NASDAQ
CRO Parexel is listed on NASDAQ

Related tags: Stock market

Parexel could repurchase up to $200m (€175m) of its stock in FY 2016, but one analyst says the firm remains committed to it M&A strategy.

As of June 30 - the end of its fiscal year - contract research organisation (CRO) Parexel had approximately $207m cash and a line of credit worth $250m available.

Yesterday, the firm announced it a stock repurchase programme, authorising the buy-back of up to $200m of its common shares as part of its commitment “to optimising the capital structure of the Company,”​ CEO Josef von Rickenbach said in a statement.

“The strength of our business fundamentals allows us to demonstrate our confidence through this stock repurchase program,”​ he continued, adding the firm was “positive about the long-term growth and profitability opportunities that lie ahead of us.”

While the programme authorises $200m worth of stock, Parexel is not obligated to acquire any. However, last year the firm approved a share repurchase scheme for $150m on June 2, and less than two weeks later announced it was buying back the said amount from Goldman Sachs.

For FY2016, Citibank analyst Garen Sarafian estimates the CRO will repurchase $175m of stock and continue an M&A strategy which has seen the addition of numerous companies over the past few of years.

“Despite today’s announcement, we believe Parexel is committed to tuck-in M&A, which management indicated was a priority for capital allocation as recently as last quarter’s earnings call,” ​Sarafian said in a note.

“We expect the company will continue to focus on broadening its asset base and see key areas of focus including among others, technology, clinical expertise, and to a lesser extent expanding geographies.”

Any deals would most likely be bolt-ons, similar in vain to the additions of pharmacovigilance firm QSI bought in April​, RTSM supplier ClinIntel acquired last October​, and Atlas Medical in July 2014​ which added Middle-Eastern trial sites to Parexel’s network.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars